Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.58 |
| ▸ | DRD3 | P35462 | 4/20 | 0.58 |
| ▸ | HTR1A | P08908 | 7/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205882 | 0.88 | DRD2 (0.49) | DRD2DRD3HTR1AADRA1AHTR7 | |
| SCHEMBL7212903 | 0.87 | PARP1 (0.50) | DRD2DRD3HTR1AHTR7DRD4 | |
| SCHEMBL7205499 | 0.77 | HTR2A (0.48) | DRD2DRD3HTR1AADRA1AHTR7 | |
| Fumaric Acid SCHEMBL7205485 | 0.75 | HTR1A (0.84) | DRD2DRD3HTR1AADRA1A | |
| Fumaric Acid SCHEMBL7205492 | 0.75 | HTR1A (0.84) | DRD2DRD3HTR1AADRA1A | |
| SCHEMBL8002128 | 0.74 | HTR1A (0.75) | HTR1AADRA1AHTR7DRD4 | |
| SCHEMBL7205665 | 0.74 | HTR7 (0.46) | DRD3HTR1AHTR7HTR2AHTR2C | |
| SCHEMBL6192921 | 0.72 | HTR1A (0.67) | DRD2DRD3HTR1AADRA1ANPC1 | |
| SCHEMBL9028512 | 0.72 | KDM4E (0.68) | DRD2DRD3HTR1AADRA1AHTR2A | |
| SCHEMBL6526368 | 0.71 | DRD2 (0.85) | DRD2DRD3HTR1AADRA1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | claimed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | claimed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | claimed |
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6313141-B1 | FOR THERAPY OF SCHIZOPHRENIA, PSYCHOTIC DEPRESSION, MANIA, PARKINSON'S DISEASE AND TARDIVE DISKINESIA | NEUROGEN CORPORATION | 2001-11-06 | — | — | US | disclosed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5972945-A | FOR TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | SLC6A3, DRD4, ADRA2C | DRD2 4/4885DRD3 7/4885HTR1A 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.